Cite
HARVARD Citation
Guglielmelli, P. et al. (2016). Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis. British journal of haematology. pp. 938-940. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Guglielmelli, P. et al. (2016). Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis. British journal of haematology. pp. 938-940. [Online].